2017 revenues: $7,824,100,000
2017 R&D spend: $367,400,000
Fiscal year ending: December 31, 2017
Bryan Hanson, president, CEO; Daniel Florin, EVP, CFO; Aure Bruneau, group president, spine, CMF, thoracic and surgery assisting technology; Tony Collins, VP, controller & chief accounting officer; Derek Davis, VP, global integration; Robert Delp, president, Americas; Didier Deltort, president, EMEA; Rachel Ellingson, SVP, strategy; William (Bill) Fisher, SVP, global HR; Monica Kendrick, VP, corporate communications; David Kunz, SVP, global quality & regulatory affairs; Coleman (Cole) Lannum, SVP, investor relations; Angela Main, VP, global chief ethics & compliance officer, associate GP; Pedro Malha, group VP, global dental division; David Nolan Jr., president, biologics, extremities, sports medicine, surgical, trauma, foot & ankle, office-based technologies & Zimmer Biomet signature solutions; Chad Phipps, SVP, GC, secretary; Zeeshan Tariq, VP, CIO; Kenneth Tripp, SVP global operations and logistics; Daniel Williamson, group president, joint reconstruction; Sang Yi, president, Asia Pacific
New CEO Bryan Hanson – hired last year from Medtronic to effect a turnaround for the ailing orthopedics giant – saw the first fruit of his efforts in 2018 when Zimmer Biomet posted first- and second-quarter earnings that beat Wall Street’s expectations. To maintain that trend Hanson has to keep executing on the financial side while overcoming FDA red flags at a plant in Warsaw, Ind., and ongoing supply chain issues affecting its inventory.